Acne Vulgaris Clinical Trial
Official title:
Lipidome and Microbiome Profile of Acne
Verified date | December 2023 |
Source | University of California, Davis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Lipidome and microbiome analysis in subjects with acne on doxycycline. Investigators will look at the skin lipidome, blood lipidome, gut micro biome and skin micro biome. Investigators will look at the changes between acne subjects and control participants, but also the changes that occur after the use of antibiotics and how this is altered.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | January 2027 |
Est. primary completion date | January 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years and older |
Eligibility | Inclusion Criteria: - Aged 15 and older - Subjects/parents/legal guardian is able to read and comprehend study procedure and consent forms. - Have already been prescribed Doxycycline by their physician for acne or to be eligible to be prescribed Doxycycline for acne - Have acne that is diagnosed by a board certified dermatologist. Exclusion Criteria: - Those who have received systemic antibiotics within four weeks of starting the study. - Those who have received systemic isotretinoin within six weeks of starting the study. - Those with seborrheic dermatitis, rosacea, or polycystic ovary syndrome - Those who are pregnant, prisoners or cognitively impaired. - Those subjects who are currently using proton pump inhibits (as studies have shown this may impact the gut microbiome) (4) - Those who have a BMI greater than >30 kg/m2, as studies have shown a reduction in the variability of intestinal microbes within this population (5). - Those who have initiated or changed brand of oral contraceptive pill within 4 weeks of starting the study. - Those who have autoimmune disorders as this group has been shown to have an altered microbiome (6) - Those who have diabetes (6), immunodeficiencies (7), inflammatory bowel disease (6), hypercholesterolemia, as these groups have been shown to have altered gut microbiomes - Those who have taken oral probiotic supplements (8) within 4 weeks of starting the study - Given the nature of the instructions that need to be adhered to for accurate collection of samples and this data, non-English speaking individuals will be excluded from this pilot study. - Allergies to the tetracycline group of antibiotics - Those who do not fit the inclusion criteria |
Country | Name | City | State |
---|---|---|---|
United States | UC Davis Dept of Dermatology | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the diversity of the gut microbiome in those with and without acne. | The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. | 2 years | |
Primary | Change in the diversity of the gut microbiome before and after the treatment of doxycycline in those with acne. | The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. | 2 years | |
Secondary | Change in global acne grade score | 2 years | ||
Secondary | Change in the investigator global assessment of acne | 2 years | ||
Secondary | Change in the lesion count of inflammatory and non-inflammatory lesions | 2 years | ||
Secondary | Change in the diversity of the skin microbiome in those with and without acne | The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. | 2 years | |
Secondary | Change in the diversity of the skin microbiome before and after treatment with doxycycline in those with acne | The diversity will be evaluated by assessing the Bray-Curtis dissimilarity index and the Shannon diversity of the bacterial DNA in the gut microbiome. | 2 years | |
Secondary | Change in the diversity of the skin lipidome in those with and without acne | The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. | 2 years | |
Secondary | Change in the skin lipidome before and after treatment with doxycycline in those with acne | The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. | 2 years | |
Secondary | Change in the diversity of the blood lipidome in those with and without acne | The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. | 2 year | |
Secondary | Change in the blood lipidome before and after treatment with doxycycline in those with | The lipid profile will include quantitation of the fatty acid profiles and presence of long chain fatty acids and short chain fatty acids. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 |